Evidence Against an Important Role of Plasma Insulin and Glucagon Concentrations in the Increase in EGP Caused by SGLT2 Inhibitors
暂无分享,去创建一个
R. DeFronzo | M. Abdul-Ghani | C. Triplitt | E. Cersosimo | John Adams | Hussein Al-Jobori | Mariam Alatrach | Christina Agyin | Robert A. Martinez | A. M. Ali | Nitchakarn Laichuthai | Olga Lavynenko | N. Laichuthai
[1] R. DeFronzo,et al. Empagliflozin and Kinetics of Renal Glucose Transport in Healthy Individuals and Individuals With Type 2 Diabetes , 2017, Diabetes.
[2] J. Holst,et al. No direct effect of SGLT2 activity on glucagon secretion , 2019, Diabetologia.
[3] R. DeFronzo,et al. Renal, metabolic and cardiovascular considerations of SGLT2 inhibition , 2017, Nature Reviews Nephrology.
[4] M. Halliwell,et al. Fasting and post-prandial splanchnic blood flow is reduced by a somatostatin analogue (octreotide) in man. , 1991, Clinical science.
[5] R. DeFronzo,et al. Combination Therapy With Canagliflozin Plus Liraglutide Exerts Additive Effect on Weight Loss, but Not on HbA1c, in Patients With Type 2 Diabetes , 2020, Diabetes Care.
[6] T. Pieber,et al. Shift to Fatty Substrate Utilization in Response to Sodium–Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes , 2016, Diabetes.
[7] Maria J. Pereira,et al. Glucagon Levels During Short-Term SGLT2 Inhibition Are Largely Regulated by Glucose Changes in Patients With Type 2 Diabetes , 2018, The Journal of clinical endocrinology and metabolism.
[8] M. Zinner,et al. Effect of exogenous somatostatin infusion on gastrointestinal blood flow and hormones in the conscious dog. , 1985, Gastroenterology.
[9] F. Pattou,et al. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion , 2015, Nature Medicine.
[10] G. Shulman,et al. Regulation of hepatic glucose metabolism in health and disease , 2017, Nature Reviews Endocrinology.
[11] S. R. Wagle,et al. Studies on the mechanism of action of somatostatin on renal gluconeogenesis: evidence for the involvement of alpha 1-adrenergic stimuli. , 1982, Archives of biochemistry and biophysics.
[12] A. Cherrington,et al. Banting Lecture 1997. Control of glucose uptake and release by the liver in vivo. , 1999, Diabetes.
[13] R. DeFronzo,et al. Renal sodium-glucose cotransporter inhibition in the management of type 2 diabetes mellitus. , 2015, American journal of physiology. Renal physiology.
[14] M. Zinner,et al. The effect of somatostatin on central hemodynamics, renal blood flow, and renal function in dogs. , 1985, Surgery.
[15] R. DeFronzo,et al. Endogenous Glucose Production and Hormonal Changes in Response to Canagliflozin and Liraglutide Combination Therapy , 2018, Diabetes.
[16] R. DeFronzo,et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. , 2014, The Journal of clinical investigation.
[17] T. Heise,et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. , 2014, The Journal of clinical investigation.